Allogeneic hematopoietic stem cell transplantation in congenital disorders: A single-center experience.
Maura FaraciStefano GiardinoFrancesca BagnascoGiuseppe MorrealeM Paola TerranovaDaniela Di MartinoEdoardo LaninoPublished in: Pediatric transplantation (2017)
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the treatment of choice for a variety of congenital disorders. We report the experience of children affected by congenital diseases other than bone marrow failure syndromes who received allo-HSCT over a period of 25 years at G. Gaslini Paediatric Research Institute. HSCTs were performed in 57 children with congenital diseases (25 with congenital immunodeficiencies, 10 with severe combined immunodeficiencies, and 22 with metabolic diseases). Overall survival rate at 3 years in the whole group of patients was 76.9%, with a trend in favor of better outcome in children with metabolic diseases and in those who received cord blood cells (85.9%) vs bone marrow cells (72.4%).
Keyphrases
- allogeneic hematopoietic stem cell transplantation
- bone marrow
- acute myeloid leukemia
- induced apoptosis
- acute lymphoblastic leukemia
- cord blood
- young adults
- mesenchymal stem cells
- cell cycle arrest
- end stage renal disease
- ejection fraction
- intensive care unit
- emergency department
- chronic kidney disease
- endoplasmic reticulum stress
- oxidative stress
- early onset
- peritoneal dialysis
- hematopoietic stem cell
- combination therapy
- drug induced
- free survival